## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.05 indicates fundamental undervaluation. Quality metrics strong (ROE 82%). Consistent execution (4/4 quarters beat estimates). Caution: declining volume (47% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($316.20)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. SteelPeak Wealth LLC Sells 52,953 Shares of Amgen Inc. $AMGN**
- Source: MarketBeat | 20260102T124325 | Bullish | Relevance: 100%
- SteelPeak Wealth LLC significantly reduced its stake in Amgen Inc. by selling 52,953 shares, now holding 90,339 shares valued at $25.49 million, making it their 29th-largest position. Despite this reduction, Amgen reported strong Q3 earnings, beating analyst expectations, and increased its quarterly dividend to $2.52 per share, yielding approximately 3.1%. The company maintains a "Moderate Buy" consensus rating with an average analyst price target of $335.35.

**2. Strong Results and Pipeline Momentum Power Amgen's (AMGN) 2025 Rally**
- Source: Finviz | 20251231T000745 | Bullish | Relevance: 100%
- Amgen Inc. (AMGN) has seen a strong rally in 2025, with its stock up over 27%, driven by robust financial results and promising clinical pipeline developments. Key products like Repatha and Tezspire showed significant sales growth, while the company's investigational obesity treatment, MariTide, has advanced to Phase 3 studies. Despite looming biosimilar competition for some drugs, Amgen's dividend outlook remains strong, supported by consistent increases and a healthy payout ratio.

**3. Mattern Capital Management LLC Buys 4,411 Shares of Amgen Inc. $AMGN**
- Source: MarketBeat | 20260102T113444 | Bullish | Relevance: 100%
- Mattern Capital Management LLC increased its stake in Amgen (NASDAQ:AMGN) by 13% during the third quarter, purchasing an additional 4,411 shares to hold a total of 38,304 shares valued at $10.81 million. This makes Amgen its 21st largest holding, representing approximately 1.3% of its portfolio. Amgen also reported strong financial results, beating earnings and revenue expectations in its latest quarter, increased its quarterly dividend to $2.52 per share, and provided optimistic guidance for FY2025 EPS.

**4. Amgen Inc. $AMGN Shares Sold by Miracle Mile Advisors LLC**
- Source: MarketBeat | 20260102T110046 | Bullish | Relevance: 100%
- Miracle Mile Advisors LLC significantly reduced its stake in Amgen Inc. by 38.5% in Q3 2025, selling 6,677 shares, though institutional investors still own a substantial portion of the company. Additionally, several Amgen executives, including EVP Murdo Gordon and SVP Nancy A. Grygiel, sold shares totaling over $3.6 million in the last quarter. Despite these sales, Amgen surpassed Q3 earnings expectations, announced a dividend increase, and received several analyst upgrades, with many maintaining a "buy" rating.

**5. VIRGINIA RETIREMENT SYSTEMS ET Al Decreases Stock Holdings in Amgen Inc. $AMGN**
- Source: MarketBeat | 20260101T121059 | Somewhat-Bullish | Relevance: 100%
- VIRGINIA RETIREMENT SYSTEMS ET Al reduced its stake in Amgen Inc. by 18.5% in the third quarter, selling 7,600 shares and holding 33,591 shares valued at $9.48 million. Despite this, Amgen reported strong Q3 earnings, beating analyst expectations, and increased its quarterly dividend to $2.52 per share, with analysts maintaining a "Moderate Buy" rating. Insider selling also occurred, with EVP Murdo Gordon and SVP Rachna Khosla reducing their holdings.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $304 | $329 | -8% |
| 2025-12-10 | Wells Fargo | $325 | $300 | +8% |
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-03 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.05 suggests fair value with growth premium. Forward P/E 14.9x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (2 raises, avg +10%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $176.4B |
| Beta | 0.45 |
| 52W Range | $257.05 - $346.38 |
| Short Interest | 2.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.05 |
| Forward P/E | 14.9 |
| Current P/E | 15.4 |
| YoY Growth | 3.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.7% over 5 days). Below STRENGTH zone by 3.1pp (needs >4.0% for momentum thesis). MRS_5 at 0.2% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 50. Volume at 47% of 20MA suggests lack of conviction. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.94% (CS: 53) | Neutral |
| RSI_14 | 50.2 | Neutral |
| MACD Histogram | -0.34 | Bearish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 1.012x | Above |
| vs SMA200 | 1.100x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $327.64
- **Stop Loss:** $316.20 (3.5% risk)
- **Target:** $350.52 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 125
- **Position Value:** $40,955.00
- **Portfolio %:** 40.96%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*